Acute hepatitis B: Is antiviral therapy necessary? Two illustrative case reports;Akute hepatitis B - Ist eine antivirale therapie indiziert? Zwei fallberichte

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 22, 2008, Pages 1178-1182

  Girke, J ^a   Wedemeyer, H ^a   Wiegand, J ^b   Manns, M P ^a   Tillmann, H L ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Acute hepatitis B; GAHB study; Lamivudine

Indexed keywords

ADEFOVIR; AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; PHOSPHONIC ACID DERIVATIVE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAUNDICE; LIVER FUNCTION; PROTHROMBIN TIME; RASH; TREATMENT OUTCOME; ACUTE DISEASE; ALGORITHM; BLOOD; DRUG COMBINATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT FAILURE;

ACUTE DISEASE; ADENINE; ADULT; ALGORITHMS; ANTIVIRAL AGENTS; BILIRUBIN; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER; MIDDLE AGED; PHOSPHONIC ACIDS; PROTHROMBIN TIME; TRANSAMINASES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 44449097685     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1077235     Document Type: Article

References (15)

1. Acharya SK, Dasarathy S, Kumer TL et al. Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. Hepatology 1996; 23: 1448-1455
2. Bernuau J, Goudeau A, Poynard T et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6: 648-651
3. Chattopadhyay S, Das BC, Hussain Z, Kar P. Hepatitis B virus genotypes in acute and fulminant hepatitis patients from north India using two different molecular genotype approaches. Hep Res 2006; 25 (2): 79-82
4. Cornberg M, Protzer U, Dollinger MM et al. Prophylaxis, diagnosis and therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 2007; 45: 525-74
5. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55
6. Zur Situation wichtiger Infektionskrankheiten in Deutschland. Virushepatitis B, C und D im Jahr 2005. Epidemiol Bull 2006; 46: 399-407
7. Garfein RS, Bower WA, Loney CM et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40 (4): 865-873
8. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatits B (a series of cases). J Viral Hep 2004; 11 (5): 427-431
9. Kumar M, Satapathy S, Monga R et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45 (1): 97-101
10. O'Grady JG, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1192-1198
11. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E et al. Lamivudine treatment for acute hepatitis B: a pilot study. Liv Int 2004; 24 (6): 547-551
12. Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis: a multicentre study. The Study of Fulminant Hepatitis. J Gastroenterol Hepatol 1991; 6: 159-164
13. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13 (4): 256-63
14. Torii N, Hasegawa K, Ogawa M, Hashimo E, Hayashi N. Effectiveness and long- term outcome of lamivudine therapy for acute hepatitis B. Hep Res 2002; 24 (1): 34-41
15. Wedemeyer H, Cornberg M, Protzer U, Berg T, Dollinger MM. Kurzfassung der aktualisierten S3-Leitlinie "Diagnostik und Therapie der Hepatitis B". Dtsch Med Wochenschr 2007; 132 (34-35): 1775-82